This evidence provides that JNK/pSmad3L (Ser-213) is an important target for the development of chemopreventive and therapeutic measures to reduce the emergence of HCC in the context of chronic liver injury and to slow the progression of existing tumors. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.